Comparative Pharmacology
Head-to-head clinical analysis: UROVIST MEGLUMINE DIU CT versus VISIPAQUE 320.
Peer-Reviewed Evidence
Head-to-head clinical analysis: UROVIST MEGLUMINE DIU CT versus VISIPAQUE 320.
UROVIST MEGLUMINE DIU/CT vs VISIPAQUE 320
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Urovist Meglumine DIU/CT is a contrast agent containing meglumine diatrizoate, an ionic monomeric iodinated radiopaque medium. It attenuates X-rays, enhancing vascular and tissue contrast during imaging. The diatrizoate ion increases plasma osmolality, potentially causing vasodilation and hemodynamic effects.
Iodinated nonionic radiocontrast agent that attenuates X-rays and enhances vascular and tissue contrast.
Intravenous administration: 100-200 mL of a 30% solution (containing 30% meglumine diatrizoate) infused over 10-30 minutes for CT imaging. Repeated doses may be given up to a maximum total dose equivalent to 4.0 mL/kg.
Intravascular administration: Adult dose is 50-150 mL (16-48 g iodine) intravenously as a bolus or infusion, depending on the procedure. For CT imaging, typical dose is 75-150 mL at 1-3 mL/sec.
None Documented
None Documented
Terminal elimination half-life 1–2 hours in patients with normal renal function. Prolonged to >20 hours with severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is approximately 2 hours in patients with normal renal function. Clinically, clearance is prolonged in renal impairment, requiring dose adjustment.
Renal: >95% unchanged within 24 hours by glomerular filtration. Biliary/fecal: <5%.
Primarily renal via glomerular filtration; approximately 95% of the dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion is minimal (<1%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent